Literature DB >> 28597520

The impact of vaccination on RBC alloimmunization in a murine model.

P Natarajan1, M Santhanakrishnan1, C A Tormey1,2, J E Hendrickson1,3.   

Abstract

Emerging data in animal models and humans suggest that pathogen-associated and damage-associated molecular patterns variably impact RBC alloantibody formation. In this study, we tested the hypothesis that vaccinations may enhance immune responses to transfused RBCs. The Pneumovax23 vaccine decreased the magnitude of anti-KEL alloimmunization in a murine model, whereas the hepB vaccine did not impact the response; RBC transfusion did not alter immune responses to either vaccine. These data highlight the complexities of the intersection of innate and adaptive immunity and suggest that future studies investigating the pathways through which inflammation impacts alloimmunization are warranted.
© 2017 International Society of Blood Transfusion.

Entities:  

Keywords:  alloimmunization; red blood cell; vaccination

Mesh:

Substances:

Year:  2017        PMID: 28597520      PMCID: PMC5575953          DOI: 10.1111/vox.12541

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  12 in total

1.  Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells.

Authors:  Jeanne E Hendrickson; Maxime Desmarets; Seema S Deshpande; Traci E Chadwick; Christopher D Hillyer; John D Roback; James C Zimring
Journal:  Transfusion       Date:  2006-09       Impact factor: 3.157

2.  Influenza vaccination and humoral alloimmunity in solid organ transplant recipients.

Authors:  Pieter Vermeiren; Vincent Aubert; Rocco Sugamele; John-David Aubert; Jean-Pierre Venetz; Pascal Meylan; Manuel Pascual; Oriol Manuel
Journal:  Transpl Int       Date:  2014-06-17       Impact factor: 3.782

3.  Effects of influenza immunization on humoral and cellular alloreactivity in humans.

Authors:  Lara Danziger-Isakov; Leonid Cherkassky; Hanni Siegel; Mary McManamon; Kristen Kramer; Marie Budev; Deirdre Sawinski; Joshua J Augustine; Donald E Hricik; Robert Fairchild; Peter S Heeger; Emilio D Poggio
Journal:  Transplantation       Date:  2010-04-15       Impact factor: 4.939

Review 4.  Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome) - An update.

Authors:  A Watad; M Quaresma; S Brown; J W Cohen Tervaert; I Rodríguez-Pint; R Cervera; C Perricone; Y Shoenfeld
Journal:  Lupus       Date:  2017-01-06       Impact factor: 2.911

5.  Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A.

Authors:  Jesse D Lai; Paul C Moorehead; Kate Sponagle; Katharina N Steinitz; Birgit M Reipert; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2016-03-31       Impact factor: 22.113

6.  Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization.

Authors:  Alex B Ryder; Jeanne E Hendrickson; Christopher A Tormey
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998

7.  Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice.

Authors:  Weili Bao; Jin Yu; Susanne Heck; Karina Yazdanbakhsh
Journal:  Blood       Date:  2009-03-31       Impact factor: 22.113

Review 8.  Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models.

Authors:  Alex B Ryder; James C Zimring; Jeanne E Hendrickson
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

9.  Adjuvants- and vaccines-induced autoimmunity: animal models.

Authors:  Jiram Torres Ruiz; Luis Luján; Miri Blank; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 4.505

10.  Red cell alloimmunisation in patients with different types of infections.

Authors:  Dorothea Evers; Johanna G van der Bom; Janneke Tijmensen; Rutger A Middelburg; Masja de Haas; Saurabh Zalpuri; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Jaap Jan Zwaginga
Journal:  Br J Haematol       Date:  2016-08-18       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.